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Background. Colonisation of the airway by Pseudomonas spp. in cystic fibrosis has been reported to be an important determinant of decline 
in pulmonary function. 
Objective. To assess pulmonary function decline and the presence of bacterial colonisation in patients with cystic fibrosis (CF) attending a 
CF clinic in a developing country.
Methods. A retrospective audit of patients attending the CF clinic at Steve Biko Academic Hospital, Pretoria, South Africa, was performed. 
The data included spirometric indices and organisms routinely cultured from airway secretions (Pseudomonas aeruginosa (PA) and 
Staphylococcus aureus (SA)). 
Results. There were 29 study subjects. Analysis of variance for ranks (after determining that baseline pulmonary function, age, gender 
and period of follow-up were not contributing to pulmonary function decline) revealed a median decline in forced expiratory volume in 1 
second, forced vital capacity and forced expiratory flow over 25 - 75% expiration of 12%, 6% and 3%, respectively, for individuals colonised 
by PA. There was no pulmonary function decline in individuals not colonised by PA, or in individuals colonised by SA. 
Conclusion. Pulmonary function decline in this South African centre is significantly influenced by chronic pseudomonal infection. Other 
influences on this phenomenon should be explored. 
S Afr Med J 2014;104(3):191-194. DOI:10.7196/SAMJ.7222
Cystic fibrosis (CF) is a genetic disease with an 
autosomal recessive inheritance pattern. The identified 
gene, the cystic fibrosis transmembrane conductance 
regulator (CFTR), is situated on the long arm of 
chromosome 7.[1] The pathological features in CF follow 
an abnormality or dysfunction in the CFTR gene leading to abnormal 
transport of chloride and sodium across epithelial membranes. This 
involves the pancreas, biliary tract, intestines, reproductive tract, 
airway and sweat glands, and in the airway leads to airway dehydration 
and disruption of mucociliary clearance. As a result of abnormal airway 
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secretions, mucus becomes a nidus for regular infections by micro-
organisms.[2] The predominant organisms are Staphylococcus aureus 
(SA) and Pseudomonas aeruginosa (PA).[3]
Colonisation by PA has major consequences for individuals with CF, 
including more frequent respiratory infectious exacerbations, impaired 
quality of life, growth retardation and decline in pulmonary function.[4] 
The concept of colonisation of the CF airway is the subject of significant 
debate. Some authors consider that recurrent culture of PA from airway 
secretions constitutes ‘chronic infection’ rather than colonisation, since 
the latter term implies benign presence of organisms.[5] In the current 
study, colonisation was considered to occur when the same bacterium 
was isolated in at least three sputum specimens on three different 
occasions but not during an acute exacerbation.
Colonisation by PA has been reported to be the most important 
determinant of decline in lung function in subjects with CF.[6] Many 
CF centres around the world have employed measures to minimise 
the risk of, and from, PA. These measures include separation of 
chronically colonised patients from those without PA at clinics, 
aggressive eradication policies, and nebuliser and home hygiene.
Spirometric measurements of pulmonary function (particularly 
forced expiratory volume in 1 second (FEV1)) are important measures 
of disease progression and survival in CF.[7]
The rate of annual pulmonary function decline, as well as the 
associated or aetiological factors, have been explored in some 
population groups.[8,9] In South Africa, only two studies of pulmonary 
function decline in CF have been published.[10,11] 
The aim of the current study was to compare the association 
between pulmonary function measurements and the presence of 
bacterial colonisation by PA and SA in patients with CF attending 
the clinic at Steve Biko Academic Hospital (SBAH), Pretoria, South 
Africa.
Methods
A retrospective audit of the patient records of subjects followed up 
at the CF clinic at SBAH was performed. The data analysed included 
spirometry, organisms identified on regular sputum microbial culture, 
and other epidemiological variables (age at CF diagnosis, age at first 
recorded spirometry, first spirometric parameters, identification of 
PA or SA in sputum (if ever), last spirometry indices, and spirometry 
parameters performed in the middle of the period between the first 
and last spirometry). Subjects met the inclusion criteria if they had 
CF, had records of at least three pulmonary function tests, and were 
able to contribute sputa for determination of microbial colonisation, 
not associated with an acute exacerbation. CF had been diagnosed 
on the basis of two unequivocal sweat tests and confirmed by genetic 
testing in all subjects.
Patients were enrolled if they were able to perform reliable 
spirometry. It was then determined whether or not each of these 
patients had current sputum growth of PA (December 2012). The 
individuals with PA in sputa were then enrolled as PA-positive if 
they had grown the organism on three or more occasions in the last 
year. At each of these time points the growth was associated with 
spirometry performed at that visit. 
All patients had sputum collected by expectoration or induced 
with hypertonic saline by nebulisation under supervision of a 
physiotherapist. Sputa were routinely collected from every patient 
at every clinic visit. Sputum quality was ensured as representative of 
lower airway secretions by means of a Bartlett score.
The CF clinic at SBAH has 52 current patients, ranging in age 
from 8 months to 40 years. Most of the white patients are ΔF508 
homozygous or heterozygous, but the clinic has four black African and 
mixed-race CF patients with other genetic aetiologies. Ninety per cent 
of the patients have pancreatic insufficiency. Clinic practice includes 
regular attempts to eradicate PA when it is identified for the first time, 
and patients with PA are treated in separate areas. The clinic manages 
all patients according to guidelines published by the Medical and 
Scientific Advisory Committee of the South African Cystic Fibrosis 
Association. Two clinic members are executive participants.[12]
Spirometry was performed using a Koko legend spirometer 
(manufactured by nSpire Health, Inc. and supplied by SSEM 
Mthembu). Normal values were interpreted against the European 
Respiratory Society (ERS)/Polgar predicted values[13] and in 
accordance with the ERS criteria.[14] The best pulmonary function 
test value (based on FEV1) of three reproducible efforts (without 
bronchodilator administration) was recorded. FEV1, forced vital 
capacity (FVC), and forced expiratory flow over 25 - 75% expiration 
(FEF25-75) were recorded. A new decontaminated re-usable bacterial 
filter (Vibac Pulmonary Function filter) was used for each patient to 
prevent infectious cross-contamination. Spirometry was performed 
by a trained technician and equipment was calibrated daily. All values 
were expressed as percentages of expected, for age and height.
The study was approved by the Human Ethics Committee of the 
University of Pretoria.
Statistical analysis
As the data were skewed, analysis of variance (ANOVA) for ranks 
was conducted. The important analysis in the study was PA and 
SA colonisation in relation to spirometric indices. Because baseline 
pulmonary function, age, gender and period of follow-up were 
not found to be significant co-variates, an ANOVA for ranks was 
employed to assess PA and SA respectively, not adjusting for the 
latter. For change in spirometry the median and interquartile range 
(IQR) were reported. Stata 12 was used for analyses and p≤0.05 was 
considered significant. 
Results
There were 29 study subjects (median age 9.97 years, IQR 6.79 - 
21.14) who met the criteria for inclusion in the study. CF genetic 
analysis revealed that 15 individuals were ΔF508 homozygous and 
eight were ΔF508 heterozygous. The remaining six individuals 
had other less common mutations. Spirometry indices at baseline 
revealed a median (IQR) FEV1, FVC and FEF25-75 of 78% (61 - 101), 
87% (73 - 95) and 70% (38 - 106), respectively. At the end of the study, 
spirometry indices revealed a mean (IQR) FEV1, FVC and FEF25-75 
of 61% (49 - 94), 77% (52 - 94) and 43% (22 - 107), respectively. 
These were not statistically different for the total group (p>0.05). The 
median (IQR) of the spirometric variables for the patients colonised 
by PA, and those not colonised, for the study entry time point and 
study end time point are reflected in Table 1. As baseline pulmonary 
function, age, gender and period of follow-up were not found to be 
significant covariates, an ANOVA for ranks was employed to assess 
the impact of PA and SA, respectively, on change in spirometric 
indices without adjusting for the latter (Table 2).
With respect to colonisation of sputa by PA, 15 of the subjects 
attending the clinic (51.7%) were found to be colonised at study 
entry. The median age of the patients with PA colonisation was 19.9 
years (IQR 15.8 - 26.9). 
The interaction of SA and PA in individuals colonised by both 
organisms revealed no statistical significance for any spirometric 
parameter. There were three patients colonised by both organisms. 
There was no difference in the rate of decline of pulmonary 
function between individuals with the common genetic mutation 
(ΔF508) homozygous status, those with heterozygous status, or when 
another mutation was present (p>0.05 for all indices).
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Discussion
This study supports the hypothesis that that the pulmonary function 
of patients with positive Pseudomonas spp. cultures declines 
significantly over time, independent of starting pulmonary function, 
subject age or gender and period of follow-up. It is possible that the 
presence of PA is but a marker for another process that may or may 
not be related to the presence of PA. However, this seems unlikely in 
the light of what is known about PA. It is well known that CF leads to 
a decline in pulmonary function. However, this decline is different in 
different population groups.[10,15,16]
The median age of the patients colonised by PA (19.9 years) in 
this study is significantly older than in many European centres, but 
this age is not the age of first colonisation.[17,18] The high rate of PA 
colonisation in the study subjects (51.7%) is greater than in some 
international studies,[9] but is comparable to local SA studies.[10,11]
Even at study entry, patients who were colonised by PA had 
lower spirometric indices compared with patients who were not 
colonised at that stage (p=0.014, 0.0014 and 0.0061 for FEV1, FVC 
and FEF25-75, respectively). These findings mirror those of many, 
but not all, local and international studies and suggest that even in 
the developing world, where CF services may not be as robust as in 
the developed world, pulmonary function decline can be prevented 
if PA prevention and/or eradication is aggressively pursued. PA 
prevention and/or eradication may turn out to be the most cost-
effective intervention for CF individuals in developing countries.
The current study revealed that a decline in pulmonary function 
was seen only in patients colonised with PA, and not in the group 
without colonisation, and that this was true for all spirometric 
indices (p<0.05 for all parameters). However, this has not been a 
consistent finding in all studies, Amin et al.[19] in Canada having 
found that PA was not responsible for a decline in lung function. 
In contrast, in a UK study by Taylor-Robinson et al.,[16] PA infection 
was associated with a more rapid rate of lung function decline. 
Similar results, with pulmonary decline, were reported in the USA 
and the UK.[4,20-22]
In a study conducted among Swedish CF patients, overall lung 
function was well preserved with a low rate of annual decline. 
However, a more rapid lung function decline was evident in the group 
colonised by PA.[9] Similar results were obtained in the two studies 
performed in the Western Cape, South Africa,[10,11] in which the study 
populations with CF more closely resembled the current SBAH study. 
Pulmonary function decline may be expected to be more significant 
in CF subjects living in a developing country, where healthcare 
resources may not be as available as in the developed world. However, 
the current study reflects local and international data revealing that 
lung function decline is minimal in patients not colonised by PA.
Certain strains of PA, not determined in the current study, have 
been found to be more significantly associated with pulmonary 
function decline, as revealed in a Canadian study conducted by 
Aaron et al.[8] and in contrast to studies in Australia and the UK. 
In a study by Davies et al.,[23] PA infection in patients with non-CF 
bronchiectasis was shown to be a marker of disease severity, but was 
not linked to an accelerated decline in pulmonary function.
Other micro-organisms may be important in contributing to a 
decline in pulmonary function. The effect of multiple antibiotic-
resistant PA infection on the decline of pulmonary function was 
found not to be significant in a study by Ren et al.[24] Furthermore, 
compared with SA alone, SA in combination with PA has been found 
to be more deleterious.[3] This was not found in the current study, but 
the number of individuals with both SA and PA was small. Aspergillus 
spp. sensitisation and persistent carriage lead to a more rapid decline 
in lung function.[25] Similarly, airway colonisation with Candida 
albicans predicts a greater rate of FEV1 decline and hospital-treated 
exacerbations in CF.[26] These are factors that could have contributed 
to the lung function decline in the current study, but analysis of these 
organisms was not included. 
Table 1. Spirometric indices (%) at baseline and end of study for 






Total group 78 (61 - 101) 61 (49 - 94)
PA-negative 99.5 (78 - 105) 97 (60 - 107)
PA-colonised 71 (41 - 83) 50 (23 - 68)
FVC
Total group 87 (73 - 95) 77 (52 - 94)
PA-negative 93 (81 - 104) 97 (71 - 114)
PA-colonised 84 (56 - 87) 67 (41 - 80)
FEF25-75
Total group 70 (38 - 106) 43 (22 - 107)
PA-negative 105 (55 - 118) 109 (69 - 138)
PA-colonised 38 (18 - 87) 22 (11 - 42)
PA = Pseudomonas aeruginosa; IQR = interquartile range; FEV1 = forced expiratory 
volume in 1 second; FVC = forced vital capacity; FEF25-75 = forced expiratory flow over 
25 - 75% expiration.
Table 2. Change in pulmonary function variables over time 
in individuals with cystic fibrosis*
Outcome (change 
from baseline)




Negative -2 (-10 - 10)
Positive 12 (2 - 22)
FVC 0.010
Negative -7 (-12 - 4)
Positive 6 (4 - 18)
FEF25-75 0.015
Negative -18.5 (-28 - 14)
Positive 3 (-1 - 22)
SA
FEV1 0.393
Negative 6 (1 - 19)
Positive 1 (-6 - 12)
FVC 0.730
Negative 4 (-6,5 - 17,5)
Positive 0 (-8 - 18)
FEF25-75 0.679
Negative 4 (-22 - 15)
Positive -1 (-23 - 25)
ANOVA = analysis of variance; IQR = interquartile range; PA = Pseudomonas aeruginosa; 
FEV1 = forced expiratory volume in 1 second; FVC = forced vital capacity; 
FEF25-75 = forced expiratory flow over 25 - 75% expiration; SA = Streptococcus aureus.
*ANOVA for ranks controlling for baseline spirometry.
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Another finding in the SBAH study was that there was no significant 
difference in the spirometric indices for males and females. This may 
reflect the small sample size, but was interesting as two studies have 
documented a difference in lung function decline between males 
and females.[27,28] However, this finding is not consistent. In studies by 
Que et al.[29] in London and Arrington-Sanders et al.[30] in the USA, 
no significant differences in FEV1 between male and female patients 
was observed. Different populations behave differently, and there is 
therefore a real need to study this aspect in all regions of the world. 
Additionally, studies have found that female patients are at greater 
risk of being colonised by PA and have a poorer prognosis and 
decreased survival compared with male patients.[31,32] 
With regard to the spirometric index FEF25-75, this study revealed 
a marked difference between patients colonised by PA and those 
who were not colonised, with a significantly greater rate of change 
in the former group. Although this is debated, the obstruction 
to small airways is best described as FEF25-75 measurements, and 
these measurements are considered to be more sensitive than 
FEV1.[33] Numerous previous studies have revealed a decline in 
FEF25-75 over time in patients with CF.[34-36] It appears that PA has a 
very profound effect on this measure of airway function, and the 
current study reveals that it should be routinely performed in CF 
subjects, especially those colonised by PA.
Study limitations
This study was limited by the small sample size. Other limiting 
factors include lack of analyis of the multiple confounding factors 
that may be operational, including home environment, exposure to 
cigarette smoke, specific treatment modalities, differences between 
PA colonisation in males and females, and colonisation by different 
organisms. The fact that only three time points were analysed in the 
study may mask differences within these time points.
Conclusion
In this cohort of patients, carriage of PA was associated with 
worse pulmonary function measurements than in patients without 
PA when the first lung function tests were conducted, and with 
significant decline over time. Since this is not a universal finding, 
our study contributes meaningfully to the international database. 
Our findings also suggest that there are local variations in CF 
subjects and highlight the need to analyse data collected in every 
centre treating CF patients to uncover regional findings that may 
be important in guiding local health policy. Furthermore, the 
study highlights the discrepancies between spirometric indices 
in individuals with CF. More studies are required to investigate 
possible factors underlying these differences.
Presented at the Combined Congress of the South African Thoracic 
Society and the Allergy Society of South Africa, Sun City, South Africa, 
5 - 9 June 2013.
Acknowledgement. The research was made possible by Department 
of Paediatrics research funds generated by publication outputs to the 
university by the Department of Higher Education, South Africa.
References
1. Derichs N. Targeting a genetic defect: Cystic fibrosis transmembrane conductance regulator modulators 
in cystic fibrosis. Eur Respir Rev 2013;22(127):58-65. [http://dx.doi.org/10.1183/09059180.00008412]
2. Kunzelmann K, Schreiber R. Airway epithelial cells – hyperabsorption in CF? Int J Biochem Cell Biol 
2012;44(8):1232-1235. [http://dx.doi.org/10.1016/j.biocel.2012.04.012]
3. Hubert D, Réglier-Poupet H, Sermet-Gaudelus I, et al. Association between Staphylococcus aureus
alone or combined with Pseudomonas aeruginosa and the clinical condition of patients with cystic 
fibrosis. J Cyst Fibros 2013;12(5):S1569-S1993. [http://dx.doi.org/10.1016/j.jcf.2012.12.003]
4. Jarad NA, Higgs S. Factors associated with reduced FEV1 in adult patients with cystic fibrosis in a 
relatively affluent area. Chron Respir Dis 2005;2(3):133-137. 
5. Granström M, Ericsson A, Strandvik B, et al. Relation between antibody response to Pseudomonas 
aeruginosa exoproteins and colonization/infection in patients with cystic fibrosis. Acta Paediatr Scand 
1984;73(6):772-777. [http://dx.doi.org/10.1111/j.1651-2227.1984.tb17774.x]
6. Lillquist YP, Cho E, Davidson AG. Economic effects of an eradication protocol for first appearance of 
Pseudomonas aeruginosa in cystic fibrosis patients: 1995 vs. 2009. J Cyst Fibros 2011;10(3):175-180. 
[http://dx.doi.org/10.1016/j.jcf.2011.01.002]
7. Konstan MW, Wagener JS, van Devanter DR. Characterizing aggressiveness and predicting future
progression of CF lung disease. J Cyst Fibros 2009;8(Suppl 1):S15-S19. [http://dx.doi.org/10.1016/
S1569-1993(09)60006-0]
8. Aaron SD, Vandemheen KL, Ramotar K, et al. Infection with transmissible strains of Pseudomonas 
aeruginosa and clinical outcomes in adults with cystic fibrosis. JAMA 2010;304(19):2145-2153. [http://
dx.doi.org/10.1001/jama.2010.1665]
9. Dennersten U, Lannefors L, Höglund P, et al. Lung function decline in the aging Swedish cystic fibrosis 
population. Respir Med 2009;103(7):1076-1082. [http://dx.doi.org/10.1016/j.rmed.2009.01.020]
10. Morrow BM, Argent AC, Distiller GB, Zar HJ, Westwood ATR. Rate of pulmonary function decline 
in South African children with cystic fibrosis. South African Journal of Child Health 2009;3(3):73-77.
11. Zar HJ, Moore B, Argent A, Ireland J, Westwood AT. Lung function in South African children with 
cystic fibrosis. S Afr Med J 1998;88(8):994-997.
12. Medical and Scientific Committee of the South African Cystic Fibrosis Association. The South African 
Cystic Fibrosis Consensus Document 2012. 4th ed. Johannesburg: South African Cystic Fibrosis
Association, 2012.
13. Quanjer PH, Borsboom GJ, Brunekreef B, et al. Spirometric reference values for white European
children and adolescents: Polgar revisited. Pediatr Pulmonol 1995;19(2):135-142. [http://dx.doi.
org/10.1002/ppul.1950190209]
14. Standardized lung function testing. Official statement of the European Respiratory Society. Eur Respir 
J Suppl 1993;16(Mar):S1-S100.
15. Schluchter MD, Konstan MW, Davis PB. Jointly modeling the relationship between survival and
pulmonary function in cystic fibrosis patients. Stat Med 2002;21(9):1271-1287. [http://dx.doi.
org/10.1002/sim.1104]
16. Taylor-Robinson D, Whitehead M, Dederichsen F, et al. Understanding the natural progression in
%FEV1 decline in patients with cystic fibrosis: A longitudinal study. Thorax 2012;67(10):860-866.
[http://dx.doi.org/10.1136/thoraxjnl-2011-200953]
17. van Mansfeld R, Willems R, Brimicombe R, et al. Predictors of mucoid Pseudomonas colonization in 
cystic fibrosis patients. Pediatr Pulmonol 2008;43(5):463-471. [http://dx.doi.org/10.1002/ppul.20794]
18. Laurans M, Arion A, Fines-Guyon M, et al. Pseudomonas aeruginosa and cystic fibrosis: First
colonization to chronic infection. Arch Pediatr 2006;13(Suppl 1):S22-S29.
19. Amin R, Lam M, Dupuis A, Ratjen F. The effect of early Pseudomonas aeruginosa treatment on lung 
function in pediatric cystic fibrosis. Pediatr Pulmonol 2011;46(6):554-558. [http://dx.doi.org/10.1002/
ppul.21417]
20. Hoffman LR, Kulasekara HD, Emerson J, Houston LS, Burns JL, Ramsey BVV. Pseudomonas aeruginosa 
lasR mutants are associated with cystic fibrosis lung disease progression. J Cyst Fibros 2009;8(1):66-70. 
[http://dx.doi.org/10.1016/j.jcf.2008.09.006]
21. Hunter RC, Klepac-Ceraj V, Lorenzi MM, Grotzinger H, Martin TR, Newman DK. Phenazine
content in the cystic fibrosis respiratory tract negatively correlates with lung function and microbial 
complexity. Am J Respir Cell Mol Biol 2012;47(6):738-745. [http://dx.doi.org/10.1165/rcmb.2012-
0088OC]
22. McPhail GL, Acton JD, Fenchel MC, Amin RS, Seid M. Improvements in lung function outcomes 
in children with cystic fibrosis are associated with better nutrition, fewer chronic Pseudomonas 
aeruginosa infections, and dornasealfa use. J Pediatr 2008;153(6):752-757. [http://dx.doi.org/10.1016/j.
jpeds.2008.07.011]
23. Davies G, Wells AU, Doffman S, Watanabe S, Wilson R. The effect of Pseudomonas aeruginosa on
pulmonary function in patients with bronchiectasis. Eur Respir J 2006;28(5):974-979. [http://dx.doi.
org/10.1183/09031936.06.00074605]
24. Ren CL, Konstan MW, Yegin A, et al. Multiple antibiotic-resistant Pseudomonas aeruginosa and lung 
function decline in patients with cystic fibrosis. J Cyst Fibros 2012;11(4):293-299. [http://dx.doi.
org/10.1016/j.jcf.2012.02.005]
25. Fillaux J, Brémont F, Murris M, et al. Assessment of Aspergillus sensitization or persistent carriage as a 
factor in lung function impairment in cystic fibrosis patients. Scand J Infect Dis 2012;44(11):842-847. 
[http://dx.doi.org/10.3109/00365548.2012.695454]
26. Chotirmall SH, O’Donoghue E, Bennett K, Gunaratnam C, O’Neil SJ, McElvaney NG. Sputum
Candida albicans presages FEV1 decline and hospital-treated exacerbations in cystic fibrosis. Chest 
2010;138(5):1186-1195. [http://dx.doi.org/10.1378/chest.09-2996]
27. Corey M, Edwards L, Levison H, Knowles M. Longitudinal analysis of pulmonary function decline 
in patients with cystic fibrosis. J Pediatr 1997;131(6):809-814. [http://dx.doi.org/10.1016/S0022-
3476(97)70025-8]
28. Konstan MW, Morgan WJ, Butler SM, et al. Risk factors for rate of decline in forced expiratory volume 
in one second in children and adolescents with cystic fibrosis. J Pediatr 2007;151(2):134-139. [http://
dx.doi.org/10.1016/j.jpeds.2007.03.006]
29. Que C, Cullinan P, Geddes D. Improving rate of decline of FEV1 in young adults with cystic fibrosis. 
Thorax 2006;61(2):155-157. [http://dx.doi.org/10.1136/thx.2005.043372]
30. Arrington-Sanders R, Yi MS, Tsevat J, Wilmott RW, Mrus JM. Gender differences in health-related 
quality of life of adolescents with cystic fibrosis. Health Qual Life Outcomes 2006;Jan 24;4:5. 
31. Demko CA, Byard PJ, Davis PB. Gender difference in cystic fibrosis: Pseudomonas aeruginosa. J Clin 
Epidemiol 1995;48(8):1041-1049. [http://dx.doi.org/10.1016/0895-4356(94)00230-N] 
32. Chotirmall SH, Smith SG, Gunaratnam C, et al. Effect of estrogen on Pseudomonas mucoidy and
exacerbations in cystic fibrosis. N Engl J Med 2012;366(21):1978-1986. [http://dx.doi.org/10.1056/
NEJMoa1106126]
33. Tiddens HAWM, Donaldson SHD, Rosenfeld M, Paré PD. Cystic fibrosis lung disease starts in the 
small airways: Can we treat it more effectively? Pediatr Pulmonol 2010;45(2):107-117. [http://dx.doi.
org/10.1002/ppul.21154]
34. Cox DW, Kelly C, Rush R, O’Sullivan N, Canny G, Linnane B. The impact of MRSA infection in the 
airways of children with cystic fibrosis: A case-control study. Ir Med J 2011;104(10):305-308.
35. Lopes AJ, Mafort TT, de Sá Ferreira A, Santos de Castro MC, Cássia de Firmida M, de Andrade
Marques E. Is the type of chronic pulmonary infection a determinant of lung function outcomes in 
adult patients with cystic fibrosis? Monaldi Arch Chest Dis 2012;77(3-4):122-128.
36. Vilozni D, Lavie M, Sarouk I, Efrati O. Progressive flow-to-volume dysanapsis in cystic fibrosis: A 
predictor for lung transplantation? Am J Respir Crit Care Med 2012;186(1):82-87. [http://dx.doi.
org/10.1164/rccm.201202-0272OC]
Accepted 7 November 2013.
